Biden Advocates for Broadening IRA’s Program to Negotiate Drug Prices

White House Drug Price Negotiation Program Expansion

White House Reveals Plan to Expand Drug Price Negotiation Program

The Initiative

On the eve of the State of the Union address, the Biden administration unveiled plans to expand the Inflation Reduction Act’s Drug Price Negotiation Program. The aim is to lower medication and healthcare costs for U.S. consumers.

Key Changes

The White House aims to increase the negotiation cap from 20 to 50 drugs annually, focusing on essential medications for seniors like those for heart disease, cancer, and diabetes.

Additionally, there will be an expansion of rebates for pharma manufacturers if their drug price hikes exceed inflation levels.

Out-of-Pocket Spending

The administration is also looking to expand the out-of-pocket spending cap for prescription drugs to $2,000 for senior Medicare beneficiaries by 2025. This limit may extend to all private insurance providers in the future.

New Program Launch

A new program will cap Medicare Part D cost-sharing at $2 for certain generic drugs. This initiative will cover a range of generic medicines, including satins, beta-blockers, and platelet inhibitors.

Legislative Support

Biden’s proposals align with a recent bill introduced by Democratic lawmakers in the House of Representatives to expand the IRA. The legislative proposal seeks to extend the drug negotiation program to cover all individuals with private insurance.

Impact and Response

The IRA, signed into law in 2022, aims to generate significant drug cost savings for the federal government by 2031. Industry stakeholders have varied responses to the proposed expansions, with some concerns raised about the effectiveness of negotiation schemes.

Final Thoughts

While the negotiations are ongoing, stakeholders continue to monitor the outcomes closely. The Biden administration’s push for expansion reflects a broader effort to address healthcare affordability and access for all Americans.

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at or

Read More of this Story at – 2024-03-07 12:52:32

Read More US Economic News

Leave A Reply

Your email address will not be published.